Back to all research

Tesamorelin: What the Research Says

July 7, 2026

Tesamorelin is notable among growth-hormone-releasing-hormone analogs for having a substantial randomized-clinical-trial record. This overview summarizes what the published research reports, strictly within a laboratory-research context.

What Is Tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analog of GHRH, with an N-terminal modification that improves stability compared with native GHRH. It acts on the GHRH receptor to stimulate the body’s own growth-hormone release.

Mechanisms & Clinical Research

  • GH/IGF-1 axis. As a GHRH analog, tesamorelin stimulates endogenous GH secretion.
  • Visceral adipose tissue. In two Phase 3 randomized controlled trials, tesamorelin significantly reduced visceral adipose tissue and waist circumference over 26 weeks in adults with HIV-associated lipodystrophy, with extension phases showing maintenance of the effect.
  • Metabolic parameters. Research has reported reductions in trunk and hepatic fat with modest increases in lean body mass; it continues to be studied in contexts such as insulin resistance and non-alcoholic fatty liver disease.

Regulatory Status

The branded pharmaceutical tesamorelin (Egrifta) received FDA approval in 2010 for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That approval is specific to that product and indication. Research-grade tesamorelin is not the approved drug product and is supplied strictly for laboratory research use only, not for human use.

The State of the Evidence

  • Tesamorelin has one of the stronger clinical evidence bases among GHRH analogs — but that evidence pertains to the approved product and its specific approved indication.
  • Research-grade material is distinct from the approved medicine and is for laboratory research only.

Key Takeaways

  • Tesamorelin is a 44-amino-acid GHRH analog that stimulates endogenous GH.
  • Phase 3 trials of the approved product reported reductions in visceral fat in HIV-associated lipodystrophy.
  • The branded drug is FDA-approved; research-grade material is not that product and is for laboratory research only.

References

  • “Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.” PMID 22298602.
  • “Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.” PMID 25038357.
  • “Tesamorelin.” LiverTox, NCBI Bookshelf NBK548730.

Research Use, Legal Status & Handling

Material supplied for research is intended for in-vitro laboratory research use only. It is not a dietary supplement, drug, cosmetic, or food. Where an approved pharmaceutical version of a compound exists, research-grade material is not that approved product and is not intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Researchers are solely responsible for compliance with all applicable federal, state, and local laws and regulations in their jurisdiction. Research peptides are generally stored lyophilized, protected from light and heat, with reconstitution and handling performed per standard laboratory protocols.

Disclaimer: This article is provided for educational and informational purposes only and summarizes published laboratory and, where noted, clinical research. It is not medical advice or a recommendation for any form of use. Research-grade material is intended strictly for in-vitro research use only — not for human or veterinary consumption. Always consult a qualified professional regarding health-related questions.